膦甲酸钠治疗肾移植患者巨细胞病毒抗原血症及护理  

Effectiveness and nursing of foscarnet treatment in cytomegalovirus antigenemia after kidney transplantation

作　　者：罗莉[1] 梁思敏[1] 

机构地区：[1]重庆医科大学附属第一医院泌尿外科,400016

出　　处：《检验医学与临床》2007年第4期263-264,共2页Laboratory Medicine and Clinic

摘　　要：目的了解膦甲酸钠（PFA）治疗肾移植患者巨细胞病毒（CMV）抗原血症的临床疗效和不良反应，为临床用药提供依据。方法60例CMV—PP65抗原阳性肾移植患者随机分为治疗组和对照组，治疗组用PFA60mg／（kg·d）静脉滴注，治疗2～4周，对照组不使用抗病毒药物。结果治疗组用药后显效24例（80％），有效3例（10％），无效3例（10％），显效、有效病例随访6月CMV—PP65抗原无转阳，对照组随访6月无1例CMV—PP65抗原转阴。PFA的不良反应为胃肠不适、低钙、低钾及一过性血肌酐升高。结论PFA可以有效清除肾移植患者fMV-PP65抗原．不良反应轻微，一般不必停药，值得临床参考应用。Objective To observe the effectiveness and adverse effect of foscarnet treatment in patients with cytomegalovirus antigenemia after renal transplantation. Methods After renal transplantation, 60 recipients with positive CMV-PP65 antigen were divided into treatment group and control group. Randomly 30 patients in treatment group received 60 mg · kg^-1 · d^-1 of foscarnet for 2-4 weeks, and 30 patients in control group did not received any antiviral treatment. Results In treatment group, 24 cases （80%） were of efficiency, 3 cases （10%） were of utility, and 3 cases were of ineffective （10%）. The CMV-PP65 antigen kept negative in whole follow-up 6 months in the cases who were of efficiency or of utility. In control group, the CMV PP65 antigen did not transform into negative result. The side effects of foscarnet were gastrointestinal upset, hypocalcemia, hypokalemia and transient creatinine rise. Conclusion Foscarnet is effective to clear the CMV-PP65 antigen, and its side effect is mild. It is unnecessary to withdrawal when its mild side effect occurs.

关 键 词：膦甲酸钠 巨细胞病毒 肾移植 护理 

分 类 号：R559[医药卫生—血液循环系统疾病]